Cato Laurencin, M.D., Ph.D.
Cato T. Laurencin, M.D., Ph.D. earned his B.S.E. in Chemical Engineering from Princeton, his M.D., Magna Cum Laude, from the Harvard Medical School, and his Ph.D. in Biochemical Engineering/Biotechnology from M.I.T.
He is the pioneer of the field of Regenerative Engineering.
In receiving the Spingarn Medal, he was named the world’s foremost engineer-physician-scientist. Dr. Laurencin pioneered the novel use of polymeric biomaterials for treating musculoskeletal conditions. In recognition of his breakthrough achievements, the American Institute of Chemical Engineers created the Cato T. Laurencin Regenerative Engineering Founder’s Award.
Dr. Laurencin’s work spans fundamental science, applied science, and technology translation. He has received the highest honors in all areas including Chemistry (Priestley Medal), Materials Science (Von Hippel Award), Biological Engineering (Jay Bailey Award), Medical and Biological Engineering (Pierre Galletti Award) and Surgery (Nicolas Andry Award).
In science, engineering, medicine, and innovation, he is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine, and an elected Fellow of the National Academy of Inventors. He is the first surgeon in history to be elected to all four of the national academies.
Dr. Laurencin is the University Professor and Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut.
He received the American Orthopaedic Association (AOA) Distinguished Contributions to Orthopaedic Surgery Award and was inducted in the AOA Awards Hall of Fame.
He is the Chief Executive Officer of The Cato T. Laurencin Institute for Regenerative Engineering at the University of Connecticut.
Financial relationships
-
Attribution:SelfType of financial relationship:Fiduciary officerIneligible company:AlkermesTopic:Board MemberDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
-
Attribution:SelfType of financial relationship:Fiduciary officerIneligible company:MimedxTopic:Board MemberDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
-
Attribution:SelfType of financial relationship:Fiduciary officerIneligible company:HOT-BoneTopic:Board MemberDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
-
Attribution:SelfType of financial relationship:Fiduciary officerIneligible company:BiobindTopic:Board MemberDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Johnson and JohnsonTopic:ConsultantDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Globus MedicalTopic:ConsultantDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BiorezTopic:Patent RoyaltiesDate added:06/16/2023Date updated:06/16/2023Relationship end date:06/01/2026
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.